泌尿器科の共同研究・ライセンシング契約（2016年～2025年）

当レポートでは、世界のバイオ医薬品業界について調査分析し、2016年～2025年の泌尿器科の共同研究・ライセンシング契約290件に関する、契約条件などの詳細なデータを提供しています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 泌尿器科契約の動向

• イントロダクション
• 過去数年の泌尿器科パートナー契約
• 泌尿器科パートナー契約：契約タイプ別
• 泌尿器科パートナー契約：産業部門別
• 泌尿器科パートナー契約：開発段階別
• 泌尿器科パートナー契約：技術タイプ別
• 泌尿器科パートナー契約：適応症別

第3章 泌尿器科パートナー契約に関する財務的契約条件

• イントロダクション
• 泌尿器科パートナー契約に関する公開された財務条件
• 泌尿器科パートナー契約のヘッドライン金額
• 泌尿器科契約の前払い
• 泌尿器科契約のマイルストーン払い
• 泌尿器科のロイヤルティ率

第4章 主な泌尿器科契約と交渉者

• イントロダクション
• 泌尿器科のパートナー契約においてもっとも活発
• 泌尿器科分野におけるもっとも活発な交渉者のリスト
• 上位の泌尿器科契約（金額）

第5章 泌尿器科契約文書ディレクトリ

• イントロダクション
• 契約書が入手可能な泌尿器科パートナー契約

第6章 泌尿器科契約：治療標的別

• イントロダクション
• 契約：泌尿器科治療標的別
• 契約ディレクトリ
• 契約ディレクトリ - 泌尿器科契約：企業別（A～Z）（2016年～2025年）
• 契約ディレクトリ - 泌尿器科契約：技術タイプ別（2016年～2025年）
• 契約タイプの定義
• Biopharma Research Ltdについて
• Current Partnering
• Current Agreements
• Current Partneringからの近年のレポートのタイトル

Genitourinary Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 290 genitourinary deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in genitourinary dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the genitourinary field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in genitourinary dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of genitourinary deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of genitourinary deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in genitourinary deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Genitourinary Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse genitourinary collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Genitourinary Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genitourinary trends and structure of deals entered into by leading biopharma companies worldwide.

Genitourinary Collaboration and Licensing Deals includes:

• Trends in genitourinary dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of genitourinary deal records covering pharmaceutical and biotechnology
• The leading genitourinary deals by value
• Most active genitourinary licensing dealmakers

In Genitourinary Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Genitourinary Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genitourinary dealmaking

• 2.1. Introduction
• 2.2. Genitourinary partnering over the years
• 2.3. Genitourinary partnering by deal type
• 2.4. Genitourinary partnering by industry sector
• 2.5. Genitourinary partnering by stage of development
• 2.6. Genitourinary partnering by technology type
• 2.7. Genitourinary partnering by therapeutic indication

Chapter 3 - Financial deal terms for genitourinary partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for genitourinary partnering
• 3.3. Genitourinary partnering headline values
• 3.4. Genitourinary deal upfront payments
• 3.5. Genitourinary deal milestone payments
• 3.6. Genitourinary royalty rates

Chapter 4 - Leading genitourinary deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in genitourinary partnering
• 4.3. List of most active dealmakers in genitourinary
• 4.4. Top genitourinary deals by value

Chapter 5 - Genitourinary contract document directory

• 5.1. Introduction
• 5.2. Genitourinary partnering deals where contract document available

Chapter 6 - Genitourinary dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by genitourinary therapeutic target
• Deal directory
• Deal directory - Genitourinary deals by company A-Z 2016 to 2025
• Deal directory - Genitourinary deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Genitourinary partnering since 2016
• Figure 2: Genitourinary partnering by deal type since 2016
• Figure 3: Genitourinary partnering by industry sector since 2016
• Figure 4: Genitourinary partnering by stage of development since 2016
• Figure 5: Genitourinary partnering by technology type since 2016
• Figure 6: Genitourinary partnering by indication since 2016
• Figure 7: Genitourinary deals with a headline value
• Figure 8: Genitourinary deals with upfront payment values
• Figure 9: Genitourinary deals with milestone payment
• Figure 10: Genitourinary deals with royalty rates
• Figure 11: Active genitourinary dealmaking activity since 2016
• Figure 12: Top genitourinary deals by value since 2016